Meeting
2012 ASCO Annual Meeting
A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).
Authors
Axel Grothey
Mayo Clinic College of Medicine, Rochester, MN
Axel Grothey , Josep Tabernero , Philippe Rougier , Shaila Ballal , Heidi Crane , Mark D. Rutstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
01183780
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS3634)
DOI
10.1200/jco.2012.30.15_suppl.tps3634
Abstract #
TPS3634
Poster Bd #
38G
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818).
First Author: Takayuki Yoshino
Poster
2018 Gastrointestinal Cancers Symposium
TRUSTY: A randomized multicenter phase II/III study of trifluridine/tipiracil and bevacizumab versus irinotecan, fluoropyrimidine, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.
First Author: Takayuki Yoshino
Poster
2018 Gastrointestinal Cancers Symposium
Phase II study of FOLFIRI + ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD).
First Author: Naotoshi Sugimoto
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz